AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8678279 — intervention group
Group type: EXPERIMENTAL
Intervention: 700 mg mepivacaine without epinephrine
Number of subjects: 60
Study 8678279 — intervention group
Group type: EXPERIMENTAL
Intervention: 700 mg mepivacaine with 0.2 mg epinephrine (1:350,000)
Number of subjects: 60
Study 8678279 — intervention group
Group type: EXPERIMENTAL
Intervention: 700 mg prilocaine 1%
Number of subjects: 60
Study 1909693 — intervention group
Group type: EXPERIMENTAL
Intervention: Resorbable sutures (polydioxanone, PDS)
Number of subjects: 425
Study 1909693 — intervention group
Group type: COMPARATOR
Intervention: Non-resorbable sutures (polyamide, Ethilon)
Number of subjects: 425
Study 1909693 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 425
Study 6130330 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoprostenol (prostacyclin)
Number of subjects: 28
Study 6130330 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 31799473 — intervention group
Group type: EXPERIMENTAL
Intervention: Year 1 recruitment methods
Number of subjects: 187
Study 31799473 — intervention group
Group type: EXPERIMENTAL
Intervention: Year 2 recruitment methods
Number of subjects: 187
Study 31799473 — intervention group
Group type: EXPERIMENTAL
Intervention: Average cost for retained participants in Year 1
Number of subjects: 187
Study 31799473 — intervention group
Group type: EXPERIMENTAL
Intervention: Average cost for retained participants in Year 2
Number of subjects: 187
Study 30403521 — intervention group
Group type: EXPERIMENTAL
Intervention: NET-Works intervention
Number of subjects: 534
Study 26400955 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular training (NMT) group performing an injury prevention programme as a warm-up 3 times weekly for 12 weeks
Number of subjects: 40
Study 26400955 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON) completing regular warm-up exercise programme
Number of subjects: 40
Study 24611849 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based relapse prevention (MBRP)
Number of subjects: 105
Study 24611849 — intervention group
Group type: COMPARATOR
Intervention: Relapse prevention (RP)
Number of subjects: 105
Study 22495703 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy
Number of subjects: 130
Study 22495703 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy
Number of subjects: 130
Study 22495703 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (completion of three to four cycles)
Number of subjects: 130
Study 22495703 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (completion of one to two cycles)
Number of subjects: 130
Study 20002660 — intervention group
Group type: EXPERIMENTAL
Intervention: Verum acupuncture (VA)
Number of subjects: 30
Study 17668348 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaethylene infusion at 200 ng/mL
Number of subjects: 8
Study 17668348 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaethylene infusion at 50 ng/mL
Number of subjects: 8
Study 17668348 — intervention group
Group type: COMPARATOR
Intervention: Cocaethylene infusion at 0 ng/mL (placebo)
Number of subjects: 8
Study 17668348 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine injection (0.5 mg/kg)
Number of subjects: 8
Study 17668348 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine injection (0.25 mg/kg)
Number of subjects: 8
Study 16274485 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant function assessment (minimal surface tension)
Number of subjects: 20
Study 16274485 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung function assessment (FEV1, MEF(75/25%VC), MEF(25%VC))
Number of subjects: 20
Study 16274485 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant specific proteins A, C, and D
Number of subjects: 20
Study 16274485 — intervention group
Group type: EXPERIMENTAL
Intervention: Surfactant protein B (SP-B)
Number of subjects: 20
Study 12360545 — intervention group
Group type: EXPERIMENTAL
Intervention: levodopa-carbidopa and bromocriptine
Number of subjects: 31
Study 12360545 — intervention group
Group type: COMPARATOR
Intervention: selegiline
Number of subjects: 31
Study 12360545 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 31
Study 10192753 — intervention group
Group type: EXPERIMENTAL
Intervention: PPS i.v. (50 mg)
Number of subjects: 18
Study 10192753 — intervention group
Group type: EXPERIMENTAL
Intervention: PPS orally (1500 mg)
Number of subjects: 18
Study 10192753 — intervention group
Group type: COMPARATOR
Intervention: Placebo (orally)
Number of subjects: 18
Study 7479627 — intervention group
Group type: EXPERIMENTAL
Intervention: 800-kcal weight-loss program for 12 weeks
Number of subjects: 40
Study 2097905 — intervention group
Group type: EXPERIMENTAL
Intervention: 30% nitrous oxide
Number of subjects: 32
Study 2097905 — intervention group
Group type: COMPARATOR
Intervention: 100% oxygen
Number of subjects: 32
Study 393788 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol/acetaminophen (4 mg/650 mg)
Number of subjects: 120
Study 393788 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (650 mg)
Number of subjects: 120
Study 393788 — intervention group
Group type: EXPERIMENTAL
Intervention: Butorphanol/acetaminophen (2 mg/325 mg)
Number of subjects: 120
Study 393788 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 31620939 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri-containing lozenges (2 lozenges/day after brushing for 3 months with a 3-month washout)
Number of subjects: 20
Study 31620939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29380388 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoballoon (CB) ablation
Number of subjects: 50
Study 29380388 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency (RF) ablation
Number of subjects: 50
Study 28317075 — intervention group
Group type: EXPERIMENTAL
Intervention: Police-school partnership intervention
Number of subjects: 0
Study 28317075 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 25741444 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese individuals
Number of subjects: 454
Study 25741444 — intervention group
Group type: COMPARATOR
Intervention: Nonobese individuals
Number of subjects: 454
Study 23971720 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberis aristata/Silybum marianum extract 588 mg/105 mg, twice a day for 3 months
Number of subjects: 102
Study 23971720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 23971720 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberis aristata/Silybum marianum extract 588 mg/105 mg, twice a day after washout
Number of subjects: 102
Study 23971720 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberis aristata/Silybum marianum extract
Number of subjects: 102
Study 20939862 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvicol(TM)
Number of subjects: 201
Study 20939862 — intervention group
Group type: EXPERIMENTAL
Intervention: TVT(TM)
Number of subjects: 201
Study 20939862 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous fascial slings (AFS)
Number of subjects: 201
Study 19133084 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.25% NaOCl
Number of subjects: 116
Study 19133084 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine
Number of subjects: 116
Study 19133084 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% w/v povidone iodine
Number of subjects: 116
Study 19133084 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.25% NaOCl followed by sodium ascorbate
Number of subjects: 116
Study 19133084 — intervention group
Group type: COMPARATOR
Intervention: Control (no disinfectant)
Number of subjects: 116
Study 16179098 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin/vinorelbine every 4 weeks as first-line treatment
Number of subjects: 40
Study 12740739 — intervention group
Group type: COMPARATOR
Intervention: Follicular phase in sedentary women; testosterone glucuronide (TG): 1.67 +/- 0.70 nmol x mmol C -1; epitestosterone glucuronide (ETG): 2.51 +/- 0.88 nmol x mmol C -1; TG/ETG ratio: 0.72 +/- 0.26; cortisol (FLU): 10.02 +/- 0.79 nmol x mmol C -1
Number of subjects: 0
Study 12740739 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular phase in trained women; TG: 1.96 +/- 1.00 nmol x mmol C -1; ETG: 1.97 +/- 0.70 nmol x mmol C -1; TG/ETG ratio: 0.66 +/- 0.05; FLU: 11.31 +/- 3.73 nmol x mmol C -1
Number of subjects: 0
Study 12740739 — intervention group
Group type: EXPERIMENTAL
Intervention: Luteal phase in trained women; TG: 1.93 +/- 0.86 nmol x mmol C -1; ETG: 3.19 +/- 1.23 nmol x mmol C -1; TG/ETG ratio: 0.69 +/- 0.33; FLU: 9.52 +/- 3.86 nmol x mmol C -1
Number of subjects: 0
Study 10788032 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality system intervention (identification of barriers, documentation, education, feedback, and peer review)
Number of subjects: 19
Study 10788032 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality system intervention
Number of subjects: 19
Study 10788032 — intervention group
Group type: COMPARATOR
Intervention: Control practices
Number of subjects: 19
Study 8865683 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 80
Study 8865683 — intervention group
Group type: COMPARATOR
Intervention: Thrombolytic therapy
Number of subjects: 80
Study 8865683 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study 1741115 — intervention group
Group type: EXPERIMENTAL
Intervention: Tight patching
Number of subjects: 30
Study 1741115 — intervention group
Group type: EXPERIMENTAL
Intervention: Light patching
Number of subjects: 30
Study 1741115 — intervention group
Group type: COMPARATOR
Intervention: Baseline controls (contralateral eye)
Number of subjects: 30
Study 6510544 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII)
Number of subjects: 25
Study 6510544 — intervention group
Group type: COMPARATOR
Intervention: Conventional insulin injections
Number of subjects: 25
Study 30825465 — intervention group
Group type: EXPERIMENTAL
Intervention: Peanut avoidance group (carriers of the MALT1 locus)
Number of subjects: 0
Study 30825465 — intervention group
Group type: COMPARATOR
Intervention: Peanut avoidance group (non-carriers of the MALT1 locus)
Number of subjects: 0
Study 29386156 — intervention group
Group type: EXPERIMENTAL
Intervention: Malarina
Number of subjects: 100
Study 29386156 — intervention group
Group type: COMPARATOR
Intervention: Quinine Bisulphate
Number of subjects: 100
Study 27154476 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of the 7 steps of the Baby Friendly Community Initiative (BFCI)
Number of subjects: 5094
Study 24094476 — intervention group
Group type: EXPERIMENTAL
Intervention: CricKey surgical cricothyroidotomy
Number of subjects: 15
Study 24094476 — intervention group
Group type: COMPARATOR
Intervention: Open surgical cricothyroidotomy
Number of subjects: 15
Study 22021371 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide maintenance
Number of subjects: 820
Study 22021371 — intervention group
Group type: COMPARATOR
Intervention: No maintenance
Number of subjects: 820
Study 21246848 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with Tuina
Number of subjects: 40
Study 21246848 — intervention group
Group type: COMPARATOR
Intervention: Nobex (intramuscular injection)
Number of subjects: 40
Study 18261664 — intervention group
Group type: EXPERIMENTAL
Intervention: Hylan injections
Number of subjects: 60
Study 18261664 — intervention group
Group type: COMPARATOR
Intervention: Corticosteroid injections
Number of subjects: 60
Study 18261664 — intervention group
Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 60
Study 15722306 — intervention group
Group type: EXPERIMENTAL
Intervention: Sub‐Tenon's block (STB) with 3 ml of 2% lidocaine and hyaluronidase
Number of subjects: 28
Study 15722306 — intervention group
Group type: COMPARATOR
Intervention: Topical anaesthesia (TOP) with proxymetacaine 0.5% and amethocaine 1% eye drops
Number of subjects: 28
Study 12651660 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthetic Conserving Device (ACD) at 8 L/min FGF
Number of subjects: 81
Study 12651660 — intervention group
Group type: COMPARATOR
Intervention: Circle system with 1‐, 1.5‐, 3‐, and 6‐L/min FGFs
Number of subjects: 81
Study 12651660 — intervention group
Group type: EXPERIMENTAL
Intervention: Anesthetic Conserving Device (ACD)
Number of subjects: 81
Study 12651660 — intervention group
Group type: COMPARATOR
Intervention: Low‐flow circle system (1.5‐ and 1‐L/min FGFs)
Number of subjects: 81
Study 11903523 — intervention group
Group type: COMPARATOR
Intervention: Butalbital-containing analgesics
Number of subjects: 0
Study 9215287 — intervention group
Group type: EXPERIMENTAL
Intervention: tiratricol (24 micrograms/kg twice daily)
Number of subjects: 24
Study 9215287 — intervention group
Group type: COMPARATOR
Intervention: L‐T4 (1.9 micrograms/kg daily)
Number of subjects: 24
Study 8434309 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated percutaneous discectomy
Number of subjects: 141
Study 8434309 — intervention group
Group type: COMPARATOR
Intervention: Chemonucleolysis
Number of subjects: 141
Study 3315270 — intervention group
Group type: EXPERIMENTAL
Intervention: 0800 hr dosing of Armophylline (600-900 mg/24 hr)
Number of subjects: 8
Study 3315270 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 hr dosing of Armophylline (600-900 mg/24 hr)
Number of subjects: 8
Study 3315270 — intervention group
Group type: COMPARATOR
Intervention: 0800 hr and 2000 hr dosing of Armophylline (600-900 mg/24 hr)
Number of subjects: 8
Study 31309355 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 62
Study 31309355 — intervention group
Group type: COMPARATOR
Intervention: Waitlist
Number of subjects: 62
Study 29244542 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MPH)
Number of subjects: 26
Study 29244542 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX)
Number of subjects: 26
Study 29244542 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=19)
Number of subjects: 26
Study 28125763 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid every 4 weeks
Number of subjects: 416
Study 28125763 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid every 12 weeks
Number of subjects: 416
Study 28125763 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 416
Study 25823561 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise program with health counselling for four weeks
Number of subjects: 96
Study 25823561 — intervention group
Group type: COMPARATOR
Intervention: Usual care (routine clinical practice)
Number of subjects: 96
Study 24119474 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopic transcapsular iliopsoas tenotomy from the peripheral compartment (Group 1, n=10)
Number of subjects: 19
Study 24119474 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic transcapsular iliopsoas tenotomy from the central compartment (Group 2, n=9)
Number of subjects: 19
Study 22092475 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine chip (CHX)
Number of subjects: 60
Study 22092475 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurbiprofen chip (FBP)
Number of subjects: 60
Study 19747069 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin 10 mg
Number of subjects: 12
Study 19747069 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin IR 10 mg
Number of subjects: 12
Study 19747069 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 17014663 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% zinc oxide
Number of subjects: 64
Study 17014663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 15116142 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan
Number of subjects: 0
Study 15116142 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 0
Study 15116142 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 11110737 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (24 mg)
Number of subjects: 653
Study 11110737 — intervention group
Group type: EXPERIMENTAL
Intervention: Galantamine (32 mg)
Number of subjects: 653
Study 11110737 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 653
Study 9308074 — intervention group
Group type: EXPERIMENTAL
Intervention: Mianserin (maximum daily dose 90 mg) and Carbamazepine (maximum daily dose 400 mg)
Number of subjects: 32
Study 9308074 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (maximum daily dose 0.600 mg)
Number of subjects: 32
Study 8334029 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,25-dihydroxy vitamin D3 (1,25(OH)2D3) (0.25-0.50 microgram/day)
Number of subjects: 24
Study 8334029 — intervention group
Group type: EXPERIMENTAL
Intervention: 24,25-dihydroxy vitamin D3 (24,25(OH)2D3) (daily dose of 15 micrograms)
Number of subjects: 24
Study 8334029 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 1,25(OH)2D3 and 24,25(OH)2D3
Number of subjects: 24
Study 8334029 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (maximal dosage of 1 g x 3)
Number of subjects: 24
Study 31078475 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives on an escalating schedule ($4 to $50) for completing CR sessions
Number of subjects: 130
Study 31078475 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 130
Study 31078475 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives
Number of subjects: 130
Study 31078475 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who completed ≥30 sessions
Number of subjects: 130
Study 31078475 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive condition group
Number of subjects: 130
Study 29735458 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride and Metformin
Number of subjects: 0
Study 29735458 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride and Acarbose
Number of subjects: 0
Study 29735458 — intervention group
Group type: EXPERIMENTAL
Intervention: Glimepiride and Rosiglitazone
Number of subjects: 0
Study 26367325 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary therapy (4 weekly exercise sessions, 1 weekly group therapy session, 1 weekly nutritional education session)
Number of subjects: 57
Study 26367325 — intervention group
Group type: EXPERIMENTAL
Intervention: Interdisciplinary therapy
Number of subjects: 57
Study 26367325 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 57
Study 24425846 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) gel
Number of subjects: 20
Study 24425846 — intervention group
Group type: COMPARATOR
Intervention: No PRP gel (Control)
Number of subjects: 20
Study 22682911 — intervention group
Group type: EXPERIMENTAL
Intervention: Foster care intervention
Number of subjects: 0
Study 22682911 — intervention group
Group type: COMPARATOR
Intervention: Care as usual (institutional care)
Number of subjects: 0
Study 20716104 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-D presentation
Number of subjects: 160
Study 20716104 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-Dc presentation
Number of subjects: 160
Study 20716104 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-D and 3-Dc modalities
Number of subjects: 160
Study 20716104 — intervention group
Group type: COMPARATOR
Intervention: 2-D group
Number of subjects: 160
Study 17606861 — intervention group
Group type: EXPERIMENTAL
Intervention: >or=75% of visits with BP control
Number of subjects: 22576
Study 17606861 — intervention group
Group type: COMPARATOR
Intervention: <25% of visits with BP control
Number of subjects: 22576
Study 16091270 — intervention group
Group type: EXPERIMENTAL
Intervention: Famous faces
Number of subjects: 0
Study 16091270 — intervention group
Group type: COMPARATOR
Intervention: Unfamiliar faces
Number of subjects: 0
Study 16091270 — intervention group
Group type: EXPERIMENTAL
Intervention: Response latency
Number of subjects: 0
Study 16091270 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual field
Number of subjects: 0
Study 16091270 — intervention group
Group type: COMPARATOR
Intervention: Explicit familiarity decision
Number of subjects: 0
Study 12368690 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) 1 g/kg/dose x2
Number of subjects: 77
Study 12368690 — intervention group
Group type: COMPARATOR
Intervention: Methylprednisolone 30 mg/kg/dose x3
Number of subjects: 77
Study 10192750 — intervention group
Group type: EXPERIMENTAL
Intervention: Mibefradil (50 mg once daily for 1 week)
Number of subjects: 40
Study 10192750 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8868205 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine and naltrexone
Number of subjects: 98
Study 8868205 — intervention group
Group type: COMPARATOR
Intervention: Placebo and naltrexone
Number of subjects: 98
Study 2182945 — intervention group
Group type: COMPARATOR
Intervention: Diethylstilbestrol diphosphate (DES‐DP) 1.5 g 24 hr intravenous infusion from day 1 to day 7 (group A)
Number of subjects: 51
Study 2182945 — intervention group
Group type: EXPERIMENTAL
Intervention: Diethylstilbestrol diphosphate (DES‐DP) plus vindesine (VND) 3 mg/m2 intravenously on days 8, 15, and 22 (group B)
Number of subjects: 51
Study 2182945 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (A and B)
Number of subjects: 51
Study 2182945 — intervention group
Group type: EXPERIMENTAL
Intervention: DES‐DP + VND
Number of subjects: 51
Study 232017 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 0
Study 232017 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril + Hydrochlorothiazide
Number of subjects: 0
Study 30058344 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate beverage (CHO)
Number of subjects: 20
Study 30058344 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 20
Study 29504499 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrupling inhaled glucocorticoids (increase by a factor of 4)
Number of subjects: 1871
Study 29504499 — intervention group
Group type: COMPARATOR
Intervention: Non-quadrupling group (same self-management plan without dose increase)
Number of subjects: 1871
Study 29504499 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrupling inhaled glucocorticoids
Number of subjects: 1871